I actually wonder if this is an early signal that there maybe corruption inside the FDA. The goal of recruiting a BoD of this level of influence but of irrelevant skills was an attempt to control the outcome of the FDA approval process, regardless of whether the tests actually work or not.<p>The purpose of NYT article seems to be to message that while Holmes may get removed from the CEO, the shareholders are still hoping to retain the value.